🔗 Share this article

Given that the US undertakes unprecedented adjustments to its immunization recommendations, a particular individual has surfaced unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about COVID-19 shots throughout the pandemic and has concentrated on alleged fatalities following COVID-19 immunization in her short tenure at the Food and Drug Administration.

Scheduled Overhauls to Childhood Immunization Schedule

Agency leaders planned to unveil sweeping changes to the pediatric vaccine schedule in December, aligning the US with Denmark’s vaccine program, sources say – a substantial departure that would put the US out of step with a large portion of the international standard with no evidence for benefit. The planned update has been delayed until the next year.

Instead of the director of the vaccine center, Tracy Beth Høeg is listed to present at the event. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the division this year.

A Shift at the Regulatory Body

This interim role might represent a closer partnership between the drug and biologics divisions as Høeg and Prasad strengthen their influence at the agency – and it signals a renewed priority upon rolling back long-standing immunizations at the FDA.

The new acting director has often pushed for halting certain pediatric vaccine recommendations in the US to become more similar to Denmark's approach, a country with universal health coverage and a population approximately the size of the state of Wisconsin.

So far public appearances, she has kept her attention on vaccination policy – usually the purview of Prasad, head of the FDA’s CBER – as opposed to drug regulation.

Questions Over Expertise

The appointee has no apparent background in medication creation, oversight or leadership, which has been typical for past leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the agency head and CBER since March.

“She doesn’t seem to have the requisite experience” for leading the pharmaceutical oversight division, remarked Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in leading a major agency. She is not an expert in industry regulation.”

Former directors of CBER would “understand legal statutes and the research of drug development”, commented a former acting FDA commissioner. “Clearly, she has not acquired the type of experience that previous people who headed the center have had.”

This division has an vast range of responsibilities at the FDA, the former commissioner emphasized.

“Many people just pays attention on the innovative therapies, but the generic program authorizes numerous generic drugs. There’s a biosimilars division, OTC medication office and other areas, and every single one must be supervised,” Dr. Woodcock said. “The area you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a substantial management element to the role, which manages in excess of 5,000 staff members. “It is a huge administrative position, if you perform it correctly,” the former official concluded.

Agency Reaction and Contentious Policies

In response to inquiries about Dr. Høeg's fitness for the role and whether this selection indicates greater collaboration among regulatory chiefs on immunizations, a spokesperson responded that the “concerns are based on flawed presumptions”.

“Her experience aligns with the functions of her job,” the representative said, pointing to the period Dr. Høeg spent counseling the FDA commissioner on “drug safety and approval science, including computerized risk analysis and shot safety tracking”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a disputed rapid therapy clearance system that apparently concerned her preceding directors. “By what process are these therapies being selected for this fast-track system? Who makes the choices?” Dr. Howard questioned. “There’s a lot of lack of transparency going on at the regulatory body right now.”

Overall, he stated, “the agency appears to be shifting towards more relaxed regulations of most medications, aside from shots.”

Documented Track Record on Immunizations

With immunizations, Høeg has a more established, if troubling, track record, Howard observe. She authored a analysis using non-validated public submissions to determine the frequency of myocarditis after Covid vaccination. She consulted for the Florida top health official Joseph Ladapo, who allegedly have changed statistics to indicate Covid vaccinations are riskier than they are.

Part of her “desired changes” for the incoming government featured changing rules for new vaccines and halting “optional” vaccines, she said following the vote on a audio program. At the agency, Høeg has reportedly floated the idea of preventing adolescent males from receiving COVID-19 vaccines.

“She’s an thorough ideologue who begins with her beliefs and tailors the evidence to retrofit the evidence in a very misleading, fraudulent fashion,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg became part of other dissenters, {like|